These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17507601)

  • 1. How to keep kidneys safe while shrinking tumors: the conundrum of cisplatin action.
    Goligorsky MS
    Am J Physiol Renal Physiol; 2007 Jul; 293(1):F50-1. PubMed ID: 17507601
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis.
    Jiang M; Wei Q; Wang J; Du Q; Yu J; Zhang L; Dong Z
    Oncogene; 2006 Jul; 25(29):4056-66. PubMed ID: 16491117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
    Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M;
    Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
    Hayek M; Srinivasan A
    Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
    [No Abstract]   [Full Text] [Related]  

  • 5. Sodium-wasting nephropathy caused by cisplatin in esophageal cancer.
    Abdelghani L; Modha K; Albaddawi E; Subramanian S
    J Support Oncol; 2008; 6(7):305-6. PubMed ID: 18847072
    [No Abstract]   [Full Text] [Related]  

  • 6. Cisplatin: a review of toxicities and therapeutic applications.
    Barabas K; Milner R; Lurie D; Adin C
    Vet Comp Oncol; 2008 Mar; 6(1):1-18. PubMed ID: 19178659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
    Dana R; Kachhwaha VS
    Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modern methods for diagnosis and monitoring of nephrotoxicity during antitumor therapy with platinum derivatives.
    Lyubimova NV; Topchieva SV; Averinova SG; Kashkadaeva AV; Gorbunova VA; Shiryaev SV; Kushlinskii NE
    Bull Exp Biol Med; 2000 Sep; 130(9):886-91. PubMed ID: 11177273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity of cancer treatment.
    Lydon J
    Oncol Nurs Forum; 1986; 13(2):68-77. PubMed ID: 3633578
    [No Abstract]   [Full Text] [Related]  

  • 10. Electrolyte Abnormalities in Cisplatin Based Chemotherapy.
    Nikhil S; Anand AS
    Indian J Physiol Pharmacol; 2016; 60(3):298-99. PubMed ID: 29957986
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse effects of cytotoxics-platinum agents.
    Selvaratnam G; Philips RH; Mohamed AK; Radzi A
    Adverse Drug React Toxicol Rev; 1997 Aug; 16(3):171-97. PubMed ID: 9512763
    [No Abstract]   [Full Text] [Related]  

  • 12. Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
    Lee CK; Park KK; Hwang JK; Lee SK; Chung WY
    Phytother Res; 2009 Jul; 23(7):999-1005. PubMed ID: 19140122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation in cisplatin nephropathy.
    Tamano M; Ohi H
    Nephron; 1999; 81(4):442-3. PubMed ID: 10095183
    [No Abstract]   [Full Text] [Related]  

  • 14. Cisplatin nephrotoxicity affects magnesium and calcium metabolism.
    Goren MP
    Med Pediatr Oncol; 2003 Sep; 41(3):186-9. PubMed ID: 12868117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxicity from chemotherapy: prevention and management.
    Vogelzang NJ
    Oncology (Williston Park); 1991 Oct; 5(10):97-102, 105; disc. 105, 109-11. PubMed ID: 1838278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
    Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
    Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cisplatin (platidiam) and the prospects for using complex platinum compounds in the clinical chemotherapy of malignant tumors].
    Gorbunova VA
    Vopr Onkol; 1989; 35(3):325-30. PubMed ID: 2705315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testicular cancer: risks of treatment vs risks of recurrence.
    Bonn D
    Lancet Oncol; 2002 Apr; 3(4):197. PubMed ID: 12067668
    [No Abstract]   [Full Text] [Related]  

  • 20. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
    Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.